Market Momentum, Semi Surge, BOJ’s Surprise Shift 7/28/23
Squawk on the Street
00:00
Roku's 16% Pop
Biogen bought Rheata Pharmaceuticals for 172.50 a share, up from 109 yesterday. The company has an FDA approved treatment for something called Friedrich's Ataxia in the US. Peter Orzak: Big pharma buying smaller competitors will be better for innovators themselves and trajectory of innovation.
Play episode from 34:02
Transcript
